Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $37

Benzinga Newsdesk www.benzinga.com Positive 91.3%

Neg 0% Neu 0% Pos 91.3%

Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $36 to $37.